Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022

Gossamer Bio, Inc.

2021-Q3 EPS reported -$2.38

Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.
Cash, equivalents and securities $366M as of Sept 30, 2021; sufficient into H2 2023.
Phase 2 TORREY (PAH) topline results now expected H2 2022 due to COVID-19 delays.
Phase 2 SHIFT-UC (ulcerative colitis) completed enrollment; topline Q2, treat-through data Q4 2022.
GB5121 advanced to Phase 1 healthy volunteers; GB7208 (MS) Phase 1 expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.